From 39 to Two: How a Lethbridge Trial is Revolutionizing Prostate Cancer Care

LETHBRIDGE, Alberta – September 16, 2026 – For decades, a prostate cancer diagnosis came with a grueling logistical sentence: up to 39 daily radiation treatments stretched over two agonizing months. In recent years, advanced medical physics successfully compressed that timeline to five sessions. Now, a pioneering clinical trial in southern Alberta is pushing the boundaries of radiobiology even further, testing whether that curative dose can be safely delivered in just two highly personalized treatments.

Hosted at the Jack Ady Cancer Centre, the DAPAR (Dose Adapted Personalized Ablative Radiotherapy of the Prostate) trial is a watershed moment for Canadian oncology. Not only does it represent a massive leap forward in precision medicine, but it also marks the first time in Alberta's history that a researcher-led cancer clinical trial is being hosted outside the major metropolitan hubs of Calgary and Edmonton.

By decentralizing world-class research and leveraging cutting-edge imaging technology, this initiative is rewriting the rules of both medical physics and regional healthcare access.

The Physics of Precision: Compressing the Radiation Timeline

The drive to shrink radiation schedules—a process known as extreme hypofractionation—is rooted in a unique biological quirk of prostate cancer. According to the Linear-Quadratic radiobiological model, most epithelial carcinomas have an alpha/beta ratio of around 10 Gray (Gy), meaning they respond best to small, steady doses of radiation. Prostate adenocarcinoma, however, has an unusually low alpha/beta ratio, empirically estimated between 1.2 and 1.8 Gy.

Crucially, the healthy tissues surrounding the prostate, such as the bladder base and rectal wall, have a higher ratio of 3.0 to 5.0 Gy. Because the tumor is more sensitive to large doses than the surrounding organs, radiation oncologists can exploit this therapeutic window. By escalating the dose per fraction, they can selectively increase cancer cell death while sparing adjacent healthy tissue.

The global feasibility of two-fraction prostate radiotherapy was recently validated by international benchmarks, notably the UK-based HERMES trial, which demonstrated that two massive doses could be delivered safely without increasing severe acute toxicity. However, the DAPAR trial in Lethbridge introduces a groundbreaking biological twist.

Instead of delivering two static doses over eight days, the DAPAR protocol inserts a mandatory three-week biological inter-fraction interval. After the first ablative dose, patients undergo a multiparametric MRI (mpMRI). Medical physicists then measure the tumor's exact radiobiological response—tracking changes in cellularity via diffusion-weighted imaging—and dynamically modulate the dosimetry of the second fraction.

“The long-term goal is to deliver the right dose, to the right place, at the right time for each patient,” says Dr. Charles Kirkby, a Senior Medical Physicist at the Jack Ady Cancer Centre and principal investigator of the study. “This project represents a shift toward more precise, image-guided cancer care. If successful, it could redefine how prostate cancer radiotherapy is delivered, making treatment shorter, more individualized and potentially more effective without compromising safety.”

Breaking the Urban Monopoly on Clinical Research

While the medical physics behind DAPAR are revolutionary, the trial's geographical location is equally profound. Historically, advanced investigator-initiated oncology trials in Alberta have been monopolized by the Arthur J.E. Child Comprehensive Cancer Centre in Calgary and the Cross Cancer Institute in Edmonton. For patients in southern Alberta, participating in cutting-edge research—or simply receiving standard care—often meant enduring crippling travel burdens.

The Jack Ady Cancer Centre serves a catchment area of over half a million residents. For a patient living in Lethbridge, a traditional 39-fraction radiation course in Calgary requires a 360-kilometer round trip every weekday. Over two months, that amounts to more than 14,000 kilometers of driving and roughly 160 hours on the highway. Even the newer five-fraction standard demands significant travel or temporary relocation, inflicting acute financial and emotional toxicity on rural families.

By reducing the protocol to two localized visits, the DAPAR trial effectively eliminates this geographical penalty, sparing patients thousands of kilometers of travel while keeping them close to their primary support networks.

"This is the first cancer clinical trial operating out of Lethbridge and is a major milestone for the region," says Crystal Elliott, CEO of the Chinook Regional Hospital Foundation, which provided crucial capital matching for local medical physics hardware and trial nursing staff. "We are incredibly proud to support this trial that will improve access for rural and regional patients, reducing the need to travel long distances for advanced cancer care and participation in vital research."

Operating a sophisticated adaptive radiotherapy trial in a community hospital setting is a logistical triumph. It relies on an innovative hub-and-spoke model supported by the Owerko Family Centre for Clinical Trials in Calgary. The central hub manages regulatory approvals and remote data monitoring, empowering local investigators in Lethbridge to execute the clinical delivery. This collaborative infrastructure proves that world-class medical innovation does not have to be confined to tertiary academic fortresses.

A Blueprint for Decentralized Healthcare

The launch of the DAPAR trial aligns perfectly with the Government of Alberta’s 10-year strategy to expand clinical trial access across the province. The initiative serves as an operational proof-of-concept for the province's broader mandate to seamlessly integrate state-of-the-art clinical care across rural and urban divides.

“This first-of-its-kind clinical trial is great news for Alberta,” says Adriana LaGrange, Minister of Hospital and Surgical Health Services. “Alberta is becoming a leader in cancer care, and by expanding opportunities for clinical research, we are helping ensure more Albertans can benefit from the latest advances in prostate cancer treatment.”

Financial momentum is also shifting to support this decentralized vision. The trial was heavily supported by a recent $35 million commitment from the Alberta Cancer Foundation—the largest clinical trials investment in the organization's history—designed specifically to expand the province's trial footprint.

"This clinical trial is an example of what a community of donors can make possible," says Wendy Beauchesne, CEO of the Alberta Cancer Foundation. "Albertans give because they want to see better outcomes for patients and continued advances in cancer care. Their generosity is helping make innovative, patient-focused research possible right here in southern Alberta."

Over the next 24 months, the 50 patients enrolled in the DAPAR study will be closely monitored to assess biochemical failure-free survival and quality-of-life metrics. If the safety and efficacy data mirror international benchmarks, this Lethbridge-led protocol could swiftly become a new national standard. More importantly, it establishes a permanent blueprint for how complex, technology-driven clinical trials can be successfully deployed in community oncology centers, ensuring that the future of cancer care is determined by the biology of the tumor, not the postal code of the patient.